Huon $HUO $HUO.AX is the #2 salmon aquaculture business on the #ASX, and is in the midst of a takeover bid from Brazilian JBS at a 38% premium to it's recent price.
So, what does this mean for Tassal $TGR $TGR.AX, the #1 salmon aquaculture business?
Let's take a look.👇
Huon was a turnaround / asset play. The turnaround thesis is that they could improve their operating margins and FCF on what was once a great business; the asset thesis is that you can't readily get licenses for salmon aquaculture anymore. Timing was never certain..
The bid from JBS $JBSAY unleashes all that value for Huon shareholders today - including the Bender family that owns ~53% of the stock and is behind the 'strategic review'.
Huon is now valued at $440m MC, though better to look at EV due to debt levels that is now $835m.
Tassal as of Friday's close was an EV of ~$1.2bn, though I note today's stock price is already up ~8%. 👍
Tassal over the past few years has been a machine when it comes to topline revenue or EBITDA. Only looking at the salmon business, you can see at Huon's takeover price it would be worth north of $6. 👊
!!This excludes EBITDA improvements in Huon, and prawn EBITDA for Tassal!!
My thought is this is more of an asset play, so better to compare valuations based on salmon assets. Net assets for Tassal is more, and quality is better as 40% of Huon's production is from ocean pens (higher cost farming). PPE ex-prawns is arguably like for like. 🤷
In my biased opinion (disclaimer: super long TGR), I don't think it's unreasonable to think Tassal's salmon assets are worth ~$4. 🐟
What makes it hard to assess is the FCF story, and the investments in prawn CAPEX. 🍤
Tassal has been expanding their prawns at +160% CAGR in volume and operating EBITDA over past 3 years, and on 18 August 2021 are expected to be crowned the #1 supplier in Australia.
Their 10yr strategy is for ~20% CAGR, and will then be around 40% of Tassal's operating EBITDA.
Tassal has invested $175m in recent years to set up this 10yr growth story - they now have the land and ponds, so it should mostly be maintenance CAPEX only.
It's hard to value the prawns, but reasonably it's $1 to $3 based on Huon and Seafarm $SFG comparisons. 🤷
If you enjoyed this, bash the like / retweet / follow buttons.
A further update is expected 18th of August when the annual report drops.
Questions and feedback always welcome. DYOR.
Disclaimer, I'm long TGR.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Cobram Estate $CBO $CBO.AX is Australia’s largest olive oil producer, set to IPO tomorrow on 11 August 2021.
A market leader in a growing industry, here are five reasons I won’t be chasing this IPO.
Let’s take a deep dive.👇
For some context, Australia is a minor producer of olive oil compared to the undisputed global champions in southern Europe.
Much of the industry is fragmented, with nonnas having a few hectares of olive groves, though there are a couple of larger players.
1. The total market is growing at an anemic rate of 1% CAGR. While Aus 🇦🇺 and the US 🇺🇸 is higher around ~3%, it doesn’t pass my “baked beans CAGR” benchmark of 4%.
If the market is growing slower than baked beans, then the bet is more about taking market share. 🥫
For good reason, folks are looking for inflation-proof yield-generating real assets. Agricultural land and primary industries are definitely in the spot light, and Rural Funds $RFF.AX $RFF has been on a tear.
But did you know your dividends will be unfranked and grossed down?👇
Before we get into divvies, a quick plug to a previous post on agricultural land, inflation and real asset plays on the #ASX 👇
1.Investment thesis: A fast growing company; operating in a growing industry; a fragmented market with lots of potential for roll-ups; horizontal and vertical integration opportunities; aggressive management.
2.Healthia’s business model is a roll-up platform operating across allied health. Put simply, they want to acquire smaller “mum and dad” businesses to expand their geographic footprint, as well as expand into new areas of healthcare.
Midway $MWY $MWY.AX is a cyclical play on export soft woodchips. Today it's just a brief update on the market conditions, what to expect in the upcoming report - and why I increased my holdings.
Midway provided guidance of $17-19m statutory earnings, and it's going to be at the low end.
This included improving operating conditions in 2H21 and some statutory tailwinds.
Main reason for the lower end of guidance is that a Brisbane shipment was meant to go in June (FY21) but was pushed back to July (FY22) - and it's 36,000tonnes of wood worth ~$2.5m. You can see it in Graincorps $GNC STEM. In the big scheme, this doesn't matter, but good to know.
Sonic Health $SHL $SHL.AX is Australia’s largest listed imaging and diagnostics healthcare company that’s taken on the world. Will this stalwart continue its Covid-sponsored run?
Let’s take a deep dive! 👇
1. Investment Thesis: A stalwart; with Covid and long-term tailwinds; good management; runway for organic and acquisitive growth in a still fragmented market; and historically a decent safe dividend yield.
2. Full disclosure, I first owned Sonic in 2010, and sold in 2015. It kept running, but not very fast. I considered in mid 2020 buying at $26, but anchor bias made me think $22 from March 2020 was better and I sat on the sidelines!